Precision raises $25.6M in series A

Gene editing company Precision BioSciences Inc. (Durham, N.C.) raised $25.6 million in a series A round led by venBio. Other investors included Fidelity Biosciences; Amgen Ventures; Baxter Ventures; Osage University Partners; The Longevity Fund; and two undisclosed public market investors. Precision said the financing was oversubscribed.

Precision plans to use its ARCUS gene editing technology for human therapeutic, agricultural and biologics manufacturing applications. The company said ARCUS can be used to create nucleases that can insert or remove DNA from genomes. Precision did not respond to inquiries. ...